Royalty Pharma
Overview
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences industry. The firm's business model involves acquiring royalty streams from existing therapies and providing upfront capital to biopharmaceutical companies, academic institutions, and research organizations in exchange for future royalty payments. This includes co-funding late-stage clinical trials and new product launches. The company maintains a diversified portfolio of royalties on many of the industry's leading therapies.
Portfolio Companies
7
Website
royaltypharma.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Revolution Medicines | Jun 2025 | Corporate Funding | Lead |
| Kailera Therapeutics | Oct 2025 | Series B | Co-investor |
| ApiJect | May 2022 | VC Round | Lead |
| Denali Therapeutics | Dec 2025 | Strategic | Lead |
| Avillion Life Sciences | May 2014 | Early Funding | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Royalty Pharma based?
Royalty Pharma is headquartered in New York City, New York, United States.
When was Royalty Pharma founded?
Founding year information for Royalty Pharma is not publicly available.
How many portfolio companies does Royalty Pharma have?
Royalty Pharma has 7 portfolio companies in Caplight's dataset.
What are some companies in Royalty Pharma's portfolio?
Portfolio companies visible on Caplight include Revolution Medicines, Kailera Therapeutics, ApiJect, Denali Therapeutics, Avillion Life Sciences.
What was Royalty Pharma's most recent investment shown here?
Royalty Pharma's most recent investment in this portfolio sample was in Denali Therapeutics in 2025.
What sectors does Royalty Pharma focus on?
Royalty Pharma focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Royalty Pharma focus on?
Royalty Pharma typically invests at the Mid stage.
What is Royalty Pharma's AUM?
Royalty Pharma's assets under management are estimated between $18.2B and $18.3B.